The surprising effect of stress on your brain’s reward system
Science Daily: Pharmacology News
DECEMBER 4, 2024
Some people bounce back from trauma, but others get caught in depressive loops that sap the joy from their lives.
Sat.Nov 30, 2024 - Fri.Dec 06, 2024
104 
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Zepbound Bests Wegovy for Weight Loss in New Trial
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly."Given the increased interest around obesity medications, we conducted.
TRIM16 and PRC1 Are Involved in Pancreatic Cancer Progression and Targeted by Delphinidin
Chemical Biology and Drug Design
DECEMBER 5, 2024
Three pancreatic cancer-related microarray datasets (GSE183795, GSE28735, and GSE62452) were integrated. Analysis of differentially expressed genes, WGCNA, and machine learning algorithms (LASSO, XGboost, and random forest) were combined to identify genes associated with the progression of pancreatic cancer. Natural drugs, including delphinidin, which target the core genes, tripartite motif containing 16 (TRIM16), and protein regulator of cytokinesis 1 (PRC1), were then identified.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
How did humans and dogs become friends? Connections in the Americas began 12,000 years ago
Science Daily: Pharmacology News
DECEMBER 4, 2024
A new study sheds light on how long humans in the Americas have had relationships with the ancestors of today's dogs -- and asks an 'existential question': What is a dog?
Diabetes advocacy group discourages use of compounded GLP-1 drugs
BioPharma Drive: Drug Pricing
DECEMBER 2, 2024
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
More Trending
Design and Development of Novel Hybrids Based on Pyrrolo[2,1‐f][1,2,4]Triazine and 1‐(Methylpiperidin‐4‐yl) Aniline–Based Analogs: Exploring the Utility as Anticancer Agents via MERTK Inhibition
Chemical Biology and Drug Design
DECEMBER 5, 2024
A hybrid drug design approach was employed to develop novel leads ( 1K11K5 ). The molecules were synthesized via a multi-step synthetic approach and were assessed for their anticancer potential via cell viability studies, DMPK studies, and MERTK inhibition. Studies were corroborated by in silico studies. ABSTRACT Mer-tyrosine kinase (MERTK), a member of the AXL, TYRO3, and MERTK (TAM) family, is one of the promising targets for cancer treatment.
20th century lead exposure damaged American mental health
Science Daily: Pharmacology News
DECEMBER 4, 2024
Exposure to car exhaust from leaded gas during childhood altered the balance of mental health in the U.S. population, making generations of Americans more depressed, anxious and inattentive or hyperactive, according to researchers. They estimate that 151 million cases of psychiatric disorder over the past 75 years have resulted from American children's exposure to lead.
Janux impresses Wall Street with new prostate cancer drug results
BioPharma Drive: Drug Pricing
DECEMBER 3, 2024
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
Aucatzyl, a New Hope Against a Tough-to-Treat Leukemia in Adults
Drugs.com
DECEMBER 3, 2024
TUESDAY, Dec. 3, 2024 -- A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show. Aucatzyl (obecabtagene autoleucel) worked on more than three-quarters (76%) of patients with B-cell.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The Role of Artificial Intelligence (AI) and Machine Learning (ML) in Drug Repurposing
Drug Patent Watch
DECEMBER 3, 2024
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
Hidden fat predicts Alzheimer's 20 years ahead of symptoms
Science Daily: Pharmacology News
DECEMBER 2, 2024
Researchers have linked a specific type of body fat to the abnormal proteins in the brain that are hallmarks of Alzheimer's disease up to 20 years before the earliest symptoms of dementia appear, according to a new study. The researchers emphasized that lifestyle modifications targeted at reducing this fat could influence the development of Alzheimer's disease.
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
Prevention Outpaced Treatment Advances in Saving Lives From Major Cancers
Drugs.com
DECEMBER 5, 2024
THURSDAY, Dec. 5, 2024 -- “An ounce of prevention is worth a pound of cure,” founding father Benjamin Franklin once said.That’s definitely true of cancer, a new study has found.Cancer prevention and screening has saved more people from five types of.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
In-Silico Antibody Development with AlphaBind Using NVIDIA BioNeMo and AWS HealthOmics
Nvidia Developer: Drug Discovery
DECEMBER 3, 2024
Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range. Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range of diseases, from cancer to autoimmune disorders.
The heart has its own 'brain'
Science Daily: Pharmacology News
DECEMBER 4, 2024
New research shows that the heart has a mini-brain -- its own nervous system that controls the heartbeat. A better understanding of this system, which is much more diverse and complex than previously thought, could lead to new treatments for heart diseases.
Novartis wagers billions of dollars on PTC Huntington’s drug
BioPharma Drive: Drug Pricing
DECEMBER 2, 2024
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
Could High-Fructose Corn Syrup in Foods Help Speed Cancer?
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- The sugar known as fructose could be a kind of rocket fuel for cancer cells, and lowering fructose intake could be one way to fight the disease, new research suggests.Fructose is already ubiquitous in American diets, due.
Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Optimizing Generic Drug Development with Machine Learning
Drug Patent Watch
DECEMBER 4, 2024
The pharmaceutical industry is undergoing a significant transformation with the advent of machine learning methods. These methods have the potential to revolutionize the drug discovery process by enhancing the efficiency and accuracy of identifying and developing new drug candidates.
Tiny, daily bursts of vigorous incidental physical activity could almost halve cardiovascular risk in middle-aged women
Science Daily: Pharmacology News
DECEMBER 3, 2024
An average of four minutes of incidental vigorous physical activity a day could almost halve the risk of major cardiovascular events, such as heart attacks, for middle-aged women who do not engage in structured exercise, according to new research.
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier treatment regimen.
American Seniors Struggle to Pay Medical Bills More Than Peers in Other Wealthy Countries
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- American seniors still pay more for health care than their counterparts in most other wealthy countries do, despite coverage by Medicare, a new study finds.They are also more likely to postpone or skip needed care because.
Countdown to an ice-free Arctic: New research warns of accelerated timelines
Science Daily: Pharmacology News
DECEMBER 3, 2024
Scientists demonstrate how a series of extreme weather events could lead to the Arctic's first ice-free day within just a few years.
Are You Using Next-Gen Sequencing to inform AAV product and process quality? Here are 4 reasons you should
BioPharma Drive: Drug Pricing
DECEMBER 2, 2024
Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate everything from process development and production to regulatory approval.
Even Minutes-Long Exercise 'Bursts' Can Help Women's Hearts
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- Take the stairs. Tote heavy shopping bags. Walk up that hill. Play tag with a kid or a pet.Weaving these tiny bursts of vigorous physical activity into everyday life can halve a woman’s risk of a heart attack, a new study.
Common Reasons for Drug Patent Rejections and Solutions
Drug Patent Watch
DECEMBER 3, 2024
The process of obtaining a patent for a drug invention can be complex and time-consuming. Despite the best efforts of inventors and patent attorneys, many drug patent applications are rejected by patent offices. Understanding the common reasons for these rejections is crucial for overcoming them and securing patent protection for innovative pharmaceuticals.
Astronomers close to solving mystery of how universe's giant galaxies formed
Science Daily: Pharmacology News
DECEMBER 4, 2024
Astrophysicists find the birth sites of gigantic elliptical galaxies which they say gives new clues about how they were formed. The galaxies look like bulging footballs and how they were created remains a mystery to scientists -- until now.
With conflicts of interest in focus, Trump’s pick to run FDA could face scrutiny of his own industry ties
BioPharma Drive: Drug Pricing
DECEMBER 6, 2024
New Weight-Loss Advance: A Gastric Balloon You Control to Feel Full or Not
Drugs.com
DECEMBER 3, 2024
TUESDAY, Dec. 3, 2024 -- GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell, too. Now, researchers at the Massachusetts Institute.
How GPCR agonists, including antibodies, are shaping the future of metabolic care
Drug Target Review
DECEMBER 4, 2024
G protein-coupled receptors (GPCRs) represent a cornerstone of modern drug discovery due to their crucial role in regulating human physiology and their involvement in numerous diseases. Many of these receptors are key targets for addressing obesity and metabolic disorders. Confo Therapeutics , led by CEO Dr Cedric Ververken, is at the forefront of developing innovative GPCR-targeted therapies using its proprietary ConfoBody ® platform.
Temporary tattoo printed directly on the scalp offers easy, hair-friendly solution for measuring brainwaves
Science Daily: Pharmacology News
DECEMBER 2, 2024
Scientists have invented a liquid ink that doctors can print onto a patient's scalp to measure brain activity. The technology offers a promising alternative to the cumbersome process currently used for monitoring brainwaves and diagnosing neurological conditions. It also has the potential to enhance non-invasive brain-computer interface applications.
Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise
BioPharma Drive: Drug Pricing
DECEMBER 5, 2024
The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.
Let's personalize your content